% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • cydney1996 cydney1996 Mar 6, 2012 5:27 PM Flag

    Gluteusmaximus80 - Help Us Understand!!!

    The following is an exerpt from an analyst report. It is way different from what you have been saying. Please help us all understand..............

    "Last month, Boston Scientific reported weak 4Q 2011 results with sales significantly below consensus estimates and management's guidance. This sales performance is attributed to disappointing CRM and DES sales shortfalls in all regions due to market slowdown and pricing pressures. Further, Boston Scientific lost market share in the ICD (Implantable Cardioverter-Defribillators) market in the U.S.

    Boston Scientific revenue guidance for 1Q 2012 was also weak. Sales growth range is expected to be -4% to 1%, indicating further CRM market contraction and pricing headwinds. Though pricing trends are improving across a few segments, ICD and DES pricing is expected to be a negative for Boston Scientific in the near term. While management's initiative for improving the cost structure in 2012 is positive, I believe the company has to show improved top line in order to reignite investor interest in the company. Until then, I would recommend avoiding the stock."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Here is another analyst report. Please help us understand the real facts here. The posters here need your balanceed input:

      "Medtronic sales should increase further with the approval of a new stent back in February 2011. The drop in the stock price in June 2011 was related to a senate investigation launched against the company regarding the non-disclosure of serious complications related to one of Medtronic's spine surgery products. The company's major competitors include Boston Scientific (BSX), with a much lower revenue of $7 billion, along with St. Jude Medical (STJ) with $6 billion. Medtronic has the highest sales growth (around 6%) versus Boston Scientific, which has a negative growth of close to 8%. Medtronic still has the highest EPS at around $3, whereas its P/E (around 13) is lower than the industry average (around 23). Therefore, shares of Medtronic still have room to rise above current levels. I recommend buying shares of Medtronic, due to the combination of new product introductions and financial strength."

21.92+0.090(+0.41%)Apr 29 4:00 PMEDT